Literature DB >> 27403297

The role for protein tyrosine phosphatase non-receptor type 22 in regulating intestinal homeostasis.

Marianne R Spalinger1, Michael Scharl2.   

Abstract

Inflammatory bowel disease represents a chronic intestinal inflammation. Recent knowledge suggests a crucial role for genetic, immunological and bacterial factors in inflammatory bowel disease pathogenesis. Variations within the gene locus encoding PTPN22 have been associated with inflammatory bowel disease. PTPN22 is critically involved in controlling immune cell activation and thereby plays an important role in maintaining intestinal homeostasis. Although in B and T cells the mechanism showing how PTPN22 affects cell signalling pathways is well studied, its role in myeloid cells remains less defined. Regulation of the innate immune system plays an essential role in the intestine, and levels of PTPN22 in myeloid cells are drastically reduced in the intestine of inflammatory bowel disease patients. Therefore, additional studies to define the role of PTPN22 in myeloid cells might clearly enhance our understanding of how PTPN22 contributes to intestinal homeostasis.

Entities:  

Keywords:  Crohn’s disease; Inflammatory bowel disease; PTPN22; adaptive immunity; innate immunity; ulcerative colitis

Year:  2015        PMID: 27403297      PMCID: PMC4924425          DOI: 10.1177/2050640615600115

Source DB:  PubMed          Journal:  United European Gastroenterol J        ISSN: 2050-6406            Impact factor:   4.623


  62 in total

Review 1.  Innate lymphoid cells: emerging insights in development, lineage relationships, and function.

Authors:  Hergen Spits; Tom Cupedo
Journal:  Annu Rev Immunol       Date:  2012-01-06       Impact factor: 28.527

2.  PTPN22 alters the development of regulatory T cells in the thymus.

Authors:  Christian J Maine; Emma E Hamilton-Williams; Jocelyn Cheung; Stephanie M Stanford; Nunzio Bottini; Linda S Wicker; Linda A Sherman
Journal:  J Immunol       Date:  2012-04-25       Impact factor: 5.422

3.  Testing for linkage and association with rheumatoid arthritis a ptpn22 promoter polymorphism reported to be associated and linked with type 1 diabetes in the Caucasian population.

Authors:  P Dieudé; V H Teixeira; C Pierlot; F Cornélis; E Petit-Teixeira
Journal:  Ann Rheum Dis       Date:  2008-06       Impact factor: 19.103

4.  Altered B cell homeostasis is associated with type I diabetes and carriers of the PTPN22 allelic variant.

Authors:  Tania Habib; Andrew Funk; Mary Rieck; Archana Brahmandam; Xuezhi Dai; Anil K Panigrahi; Eline T Luning Prak; Almut Meyer-Bahlburg; Srinath Sanda; Carla Greenbaum; David J Rawlings; Jane H Buckner
Journal:  J Immunol       Date:  2011-11-21       Impact factor: 5.422

5.  Toll-like receptor 9-induced type I IFN protects mice from experimental colitis.

Authors:  Kyoko Katakura; Jongdae Lee; Daniel Rachmilewitz; Gloria Li; Lars Eckmann; Eyal Raz
Journal:  J Clin Invest       Date:  2005-03       Impact factor: 14.808

6.  Linkage proof for PTPN22, a rheumatoid arthritis susceptibility gene and a human autoimmunity gene.

Authors:  Laëtitia Michou; Sandra Lasbleiz; Anne-Christine Rat; Paola Migliorini; Alejandro Balsa; René Westhovens; Pilar Barrera; Helena Alves; Céline Pierlot; Elodie Glikmans; Sophie Garnier; Jean Dausset; Carlos Vaz; Manuela Fernandes; Elisabeth Petit-Teixeira; Isabelle Lemaire; Dora Pascual-Salcedo; Stefano Bombardieri; Jan Dequeker; Timothy R Radstake; Piet Van Riel; Leo van de Putte; Antonio Lopes-Vaz; Bernard Prum; Thomas Bardin; Philippe Dieudé; François Cornélis
Journal:  Proc Natl Acad Sci U S A       Date:  2007-01-19       Impact factor: 11.205

7.  A missense single-nucleotide polymorphism in a gene encoding a protein tyrosine phosphatase (PTPN22) is associated with rheumatoid arthritis.

Authors:  Ann B Begovich; Victoria E H Carlton; Lee A Honigberg; Steven J Schrodi; Anand P Chokkalingam; Heather C Alexander; Kristin G Ardlie; Qiqing Huang; Ashley M Smith; Jill M Spoerke; Marion T Conn; Monica Chang; Sheng-Yung P Chang; Randall K Saiki; Joseph J Catanese; Diane U Leong; Veronica E Garcia; Linda B McAllister; Douglas A Jeffery; Annette T Lee; Franak Batliwalla; Elaine Remmers; Lindsey A Criswell; Michael F Seldin; Daniel L Kastner; Christopher I Amos; John J Sninsky; Peter K Gregersen
Journal:  Am J Hum Genet       Date:  2004-06-18       Impact factor: 11.025

Review 8.  The role of PTPN22 in autoimmunity: learning from mice.

Authors:  Junfeng Zheng; Frank Petersen; Xinhua Yu
Journal:  Autoimmun Rev       Date:  2013-11-01       Impact factor: 9.754

9.  Structure, inhibitor, and regulatory mechanism of Lyp, a lymphoid-specific tyrosine phosphatase implicated in autoimmune diseases.

Authors:  Xiao Yu; Jin-Peng Sun; Yantao He; Xiaoling Guo; Sijiu Liu; Bo Zhou; Andy Hudmon; Zhong-Yin Zhang
Journal:  Proc Natl Acad Sci U S A       Date:  2007-12-03       Impact factor: 11.205

10.  Protein tyrosine phosphatase non-receptor type 22 modulates NOD2-induced cytokine release and autophagy.

Authors:  Marianne R Spalinger; Silvia Lang; Stephan R Vavricka; Michael Fried; Gerhard Rogler; Michael Scharl
Journal:  PLoS One       Date:  2013-08-26       Impact factor: 3.240

View more
  3 in total

1.  Experimental colitis in IL-10-deficient mice ameliorates in the absence of PTPN22.

Authors:  T Jofra; G Galvani; I Cosorich; L De Giorgi; A Annoni; A Vecchione; C Sorini; M Falcone; G Fousteri
Journal:  Clin Exp Immunol       Date:  2019-07-10       Impact factor: 4.330

2.  Deletion of Protein Tyrosine Phosphatase Nonreceptor Type 2 in Intestinal Epithelial Cells Results in Upregulation of the Related Phosphatase Protein Tyrosine Phosphatase Nonreceptor Type 23.

Authors:  Sima Ulugöl; Larissa Hering; Roberto Manzini; Ana Montalban Arques; Claudia Gottier; Silvia Lang; Michael Scharl; Marianne R Spalinger
Journal:  Inflamm Intest Dis       Date:  2019-04-10

Review 3.  Targeting protein phosphatases for the treatment of inflammation-related diseases: From signaling to therapy.

Authors:  Jie Pan; Lisha Zhou; Chenyang Zhang; Qiang Xu; Yang Sun
Journal:  Signal Transduct Target Ther       Date:  2022-06-04
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.